prior research
A quick lookie-look revealed a pubmed article discussing this very same peptide (same researchers involved, btw) not for PD but ALS, in 2009, three years ago. I seem to remember Offen and/or Melamed as being very focused on ALS. I wonder why the shift of focus for this peptide from ALS to PD? Did it not perform as hoped for ALS and so now they are looking at it for PD? If so, this does not seem good to me, since neuroprotection is neuroprotection, and if it did not show that for ALS, I would be surprised if it did for PD.
If it did show neuroprotection or disease modification for ALS, I think we would have heard about that since the pubmed article was 2009, enough time for additional work to have been done and reports to have come out. Particularly in light of the fact that three years is often the length of time for ALS. So I wonder what this shift from ALS to PD might mean, anyone know?
I can't put much stock in this news release until we know what happened to the line of work with this peptide for ALS, and also why the focus shifted to PD.
|
Linear Mode
